USRE35152E
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for the diagnosis and treatment of inflammation
Assignee: General Hospital Corp
•
Filing: 1987-01-12
•
Granted: 1996-02-06
•
Expires: 2007-01-12
Abstract
Abstract PCT No. PCT/US87/00079 Sec. 371 Date Nov. 13, 1987 Sec. 102(e) Date Nov. 13, 1987 PCT Filed Jan. 12, 1987 PCT Pub. No. WO87/04351 PCT Pub. Date Jul. 30, 1987.The invention relates to a method of detecting an inflammation site in an individual by administering to the individual a diagnostically effective amount of detectably labeled immunoglobulin or fragment thereof, wherein the immunoglobulin substantially accumulates at the site when the site is inflamed.
Inventors
- 👤 Robert H. Rubin
- 👤 H. William Strauss
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 21:34
CPC Classifications
C; C07; C07K; C07K16/00; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6801; A61K47/6803; A61K47/6811; A61K47/6817; A61K47/6835; A61K49/00; A61K49/06; A61K49/08; A61K49/10; A61K49/14; A61K49/16; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K51/1018; A61K2121/00; A61K2123/00
Claims Analysis
Total Claims: 34
Claim 1
Independent Claim
85 words
A method of detecting an inflammation site in vivo in an individual which comprises: (a) administering to said individual a diagnostically effective amount of .[.a.]. .Iadd.an .Iaddend.agent wherein said agent .[.consists essentially of.]. .Iadd.comprises .Iaddend.a detachably labeled immunoglobulin or .[.a.]. .Iadd.an Fc .Iaddend.fragment .Iadd.or subfragment .Iaddend.thereof, and said immunoglobulin.Iadd., or Fc fragment or subfragment thereof, .Iaddend.substantially accumulates at said site when said site is inflamed .Iadd.and said agent has no substantial epitopic specificity for said inflamed site.[.,.]..Iadd.; .Iaddend.and (b) detecting said .[.detectably labeled immunoglobulin.]. .Iadd.agent.Iaddend..
Claim 2
Independent Claim
85 words
A method of detecting an inflammation site in vivo in an individual which comprises: (a) administering to said individual a diagnostically effective amount of .[.a.]. .Iadd.an .Iaddend.agent wherein said agent .[.consists essentially of.]. .Iadd.comprises .Iaddend.a detachably labeled immunoglobulin or .[.a.]. .Iadd.an Fc .Iaddend.fragment .Iadd.or subfragment .Iaddend.thereof, and said immunoglobulin.Iadd., or Fc fragment or subfragment thereof, .Iaddend.substantially accumulates at said site when said site is inflamed .Iadd.and said agent has no substantial epitopic specificity for said inflamed site.[.,.]..Iadd.; .Iaddend.and (b) detecting said .[.detectably labeled immunoglobulin.]. .Iadd.agent.Iaddend..
Claim 3
Dependent Claim
21 words
The method of claim 1 wherein said .[.immunoglobulin.]. .Iadd.agent .Iaddend.does not accumulate at said site when said site is not inflamed.
Claim 4
Dependent Claim
20 words
The method of claim 1 wherein said .[.immunoglobulin.]. .Iadd.agent .Iaddend.is .[.monoclonally derived.]. .Iadd.one or more detectably labeled monoclonal antibodies. .Iaddend.
Claim 5
Dependent Claim
17 words
The method of claim 1 wherein said .[.immunoglobulin.]. .Iadd.agent .Iaddend.is .[.polyclonally derived.]. .Iadd.detectably labeled, pooled, human immunoglobulin.Iaddend..
Claim 6
Independent Claim
17 words
The method as in any one of claims 1-4, wherein said detectable label is a radioactive isotope.
Claim 7
Dependent Claim
38 words
The method of claim 5, wherein said isotope is selected from the group consisting of 99m Tc, 123 I, 131 I, 111 In, 97 Ru, 67 Cu, 67 Ga, 68 Ga, 72 As, 89 Zr, and 201 Tl.
Claim 8
Independent Claim
17 words
The method as in any one of claims 1-4, wherein said detectable label is a paramagnetic label.
Claim 9
Dependent Claim
27 words
The method of claim 7, wherein said paramagnetic label is selected from the group consisting of 157 Gd, 55 Mn, 162 Dy, 52 Cr, and 56 Fe.
Claim 10
Dependent Claim
17 words
The method of claim 7, wherein said detecting is by magnetic resonance imaging or positron emission tomography.
Claim 11
Dependent Claim
10 words
The method of claim 1, wherein said administration is parenteral.
Claim 12
Dependent Claim
18 words
The method of claim 10, wherein said parenteral administration is by intradermal, subcutaneous, intramuscular, intraperitoneal, or intravenous injection.
Claim 13
Dependent Claim
12 words
The method of claim 10, wherein said administration is by gradual perfusion.
Claim 14
Dependent Claim
15 words
The method of claim 12, wherein said gradual perfusion is by intravenous or peristaltic means.
Claim 15
Independent Claim
167 words
A method of detecting the underlying cause of an inflammatory response in vivo in an individual which comprises: (a) administering to said individual a diagnostically effective amount of .Iadd.a first agent, wherein said first agent comprises .Iaddend.a detectably labeled.Iadd., non-specific .Iaddend.immunoglobulin or .[.a.]. .Iadd.an Fc .Iaddend.fragment .Iadd.or subfragment .Iaddend.thereof, .Iadd.and .Iaddend.wherein said immunoglobulin .Iadd.or Fc fragment or subfragment .Iaddend.substantially accumulates at said site when said site is inflamed; (b) imaging said individual to detect the presence of a site of inflammation; (c) based on the presence of a site of inflammation as demonstrated by step (b), further administering to said individual a diagnostically effective amount of a detectably labeled specific antibody or a fragment thereof, wherein said detectably labeled specific antibody .Iadd.or fragment thereof .Iaddend.can .Iadd.specifically .Iaddend.bind to the underlying cause of the inflammatory response; and (d) imaging said individual to detect the presence of the detectable labeled specific antibody or fragment thereof bound to the underlying cause of the inflammation at the site of the inflammation.
Claim 16
Independent Claim
167 words
A method of detecting the underlying cause of an inflammatory response in vivo in an individual which comprises: (a) administering to said individual a diagnostically effective amount of .Iadd.a first agent, wherein said first agent comprises .Iaddend.a detectably labeled.Iadd., non-specific .Iaddend.immunoglobulin or .[.a.]. .Iadd.an Fc .Iaddend.fragment .Iadd.or subfragment .Iaddend.thereof, .Iadd.and .Iaddend.wherein said immunoglobulin .Iadd.or Fc fragment or subfragment .Iaddend.substantially accumulates at said site when said site is inflamed; (b) imaging said individual to detect the presence of a site of inflammation; (c) based on the presence of a site of inflammation as demonstrated by step (b), further administering to said individual a diagnostically effective amount of a detectably labeled specific antibody or a fragment thereof, wherein said detectably labeled specific antibody .Iadd.or fragment thereof .Iaddend.can .Iadd.specifically .Iaddend.bind to the underlying cause of the inflammatory response; and (d) imaging said individual to detect the presence of the detectable labeled specific antibody or fragment thereof bound to the underlying cause of the inflammation at the site of the inflammation.
Claim 17
Dependent Claim
21 words
The method of claim 14 which further comprises: treating the underlying cause of the inflammatory response therapeutically with an appropriate agent.
Claim 18
Dependent Claim
26 words
The method of claim 15, wherein said treating utilizes a therapeutically labeled antibody specific for said underlying cause of the inflammatory response, bound to said agent.
Claim 19
Dependent Claim
15 words
The method of claim 14, wherein said specific antibody is .[.monoclonally derived.]. .Iadd.a monoclonal antibody.Iaddend..
Claim 20
Dependent Claim
15 words
The method of claim 15, wherein said specific antibody is .[.polyclonally derived.]. .Iadd.a polyclonal antibody.Iaddend..
Claim 21
Independent Claim
15 words
The method as in any one of claims 15-16, wherein said agent is a drug.
Claim 22
Independent Claim
15 words
The method as in any one of claims 15-16, wherein said agent is a lectin.
Claim 23
Dependent Claim
13 words
The method of claim 20, wherein said lectin is the alpha-chain of ricin.
Claim 24
Independent Claim
15 words
The method as in any one of claims 15-16, wherein said agent is a toxin.
Claim 25
Dependent Claim
11 words
The method of claim 22, wherein said toxin is diphtheria toxin.
Claim 26
Independent Claim
16 words
The method as in any one of claims 15-16, wherein said agent is a radioactive isotope.
Claim 27
Dependent Claim
35 words
The method of claim 24, wherein said radioactive isotope is selected from the group consisting of 125 I, 131 I, 90 Y, 67 Cu, 217 Bi, 211 At, 212 Pb, 47 Sc, or 109 Pd.
Claim 28
Independent Claim
15 words
The method as in any one of claims 15-16, wherein said agent is an antimicrobial.
Claim 29
Dependent Claim
24 words
The method of claim 26, wherein said antimicrobial is selected from the group consisting of an anti-bacterial, an anti-fungal, an anti-viral, and an anti-parasitic.
Claim 30
Dependent Claim
13 words
The method of claim 1 or 14, wherein said individual is a human.
Claim 31
Dependent Claim
29 words
The method of claim 1 or 14, wherein said inflammation is a result of a microbial infection, a viral infection, a trauma, an autoimmune process, or a tumor. .Iadd.
Claim 32
Independent Claim
79 words
A method of detecting an inflammation site in vivo in an individual which comprises: (a) administering to said individual a diagnostically effective amount of an agent wherein said agent comprises a detachably labeled immunoglobulin or an Fc fragment or subfragment thereof, and said immunoglobulin, or Fc fragment or subfragment thereof, substantially accumulates at said site when said site is inflamed wherein said accumulation is substantially independent of the epitopic specificity of the immunoglobulin; and (b) detecting said agent..Iaddend. .Iadd.
Claim 33
Independent Claim
79 words
A method of detecting an inflammation site in vivo in an individual which comprises: (a) administering to said individual a diagnostically effective amount of an agent wherein said agent comprises a detachably labeled immunoglobulin or an Fc fragment or subfragment thereof, and said immunoglobulin, or Fc fragment or subfragment thereof, substantially accumulates at said site when said site is inflamed wherein said accumulation is substantially independent of the epitopic specificity of the immunoglobulin; and (b) detecting said agent..Iaddend. .Iadd.
Claim 34
Dependent Claim
65 words
The method of claim 30, wherein said agent is one or more detectably labeled monclonal antibodies..Iaddend. .Iadd.32. The method of claim 3, wherein said one or more detectably labeled monoclonal antibodies are murine monoclonal antibodies..Iaddend. .Iadd.33. The method of claim 17, wherein said monoclonal antibody is a murine monoclonal antibody..Iaddend. .Iadd.34. The method of claim 31, wherein said monoclonal antibody is a murine monoclonal antibody..Iaddend.
References Cited (Backward Citations)
BE829128A
Cited
US4057617A
Cited
BE832363R
Cited
US4293537A
Cited
US4424200A
Cited
US4315906A
Cited
US4444744A
Cited
US4472509A
Cited
US4479930A
Cited
WO1985003231A1
Cited
US4636380A
Cited
US4639365A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-02-05 | 1999-08-07 | 2000-02-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-02-05 | 2003-08-07 | 2004-02-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-02-05 | 2007-08-07 | 2008-02-06 | $7700.00 | Window Closed / Lapsed |